论文部分内容阅读
一项调查显示,我国60岁以上的老人有1.3亿,占世界老龄人口的1/5,占亚洲老龄人口的一半以上;到下世纪中叶,60岁以上的老人将达4亿左右。这是个沉重的社会负担,同时也给“银色产业”的发展带来了巨大的商机。老年药物市场开发大有可为据有关方面测算,今年我国65岁以上的老年人口将占总人口的7%以上。其中,北京已达到14%,天津8.65%,上海13%,广东、山东、福建、浙江等经济发达省市都已大大超过7%。这些数据表明我国已开始进入老龄化社会。医药企业如何面对这一日益庞大的消费和服务群体,已成为其能否赢得市场的关键。老年病有难治性、隐匿性和多器官损害的特点,治疗用药还得考虑相互影响。来自上海的抽样调查发现,1.5万余名65岁以上的老年人中,约77%患有各种慢性病。其中循环系统、消化系统、呼吸系统疾病和糖尿病分列前4位,另有不少人患有心脏病、高血压和关节炎。这就为众多
According to a survey, there are 130 million elderly people over the age of 60 in our country, accounting for one-fifth of the world’s elderly population, accounting for more than half of the elderly in Asia. By the middle of the next century, the number of elderly people over the age of 60 will reach about 400 million. This is a heavy social burden and a tremendous business opportunity for the development of “silver industry.” According to the estimates of relevant parties, the elderly population over the age of 65 in China will account for over 7% of the total population this year. Among them, Beijing has reached 14%, Tianjin 8.65%, Shanghai 13%, Guangdong, Shandong, Fujian, Zhejiang and other economically developed provinces and cities have greatly exceeded 7%. These figures show that our country has begun to enter an aging society. How pharmaceutical companies face this growing consumer and service community has become the key to their ability to win the market. Alzheimer’s disease is refractory, occult and multiple organ damage characteristics, treatment medication have to consider the interaction. A sample survey from Shanghai found that about 77% of the more than 15,000 elderly people over the age of 65 suffer from various chronic diseases. Among them, the circulatory system, digestive system, respiratory diseases and diabetes ranked the top 4, and many others suffered from heart disease, high blood pressure and arthritis. This is numerous